Sankyo Pharma Inc. Halts Development Of Pactimibe (CS-505)
10/26/2005 12:06:24 PM
The drug industry is facing slowing growth, particularly in the key U.S. market, which accounts for 43% of worldwide pharmaceutical sales. Even Pfizer, the world's largest drug company, is having trouble delivering on its earnings per share targets. The company withdrew guidance for 2006 through 2007 last week.
Now, one more promising approach to treating heart disease may have just gone down the drain, providing further evidence of the drug industry's worldwide research drought.
Last night in Tokyo, Sankyo Pharma said it had halted development of pactimibe, or CS-505, a new drug designed to prevent cholesterol from sticking to the arteries. A U.S. phase II trial had also failed show any efficacy from the drug. It was hoped that such a drug could be added to blockbuster cholesterol-lowering medicines such as Lipitor and Zocor to further cut the number of heart attacks and strokes, the leading cause of death in the developed world.